IAM's annual IP benchmarking survey opens today
USPTO head tells Washington DC event that the next head of the organisation must come from a country that “respects intellectual property rights”
IAM is currently seeking nominations for individuals to be considered for the 2020 edition of the Strategy 300 - our unique guide to the men and women who excel in the creation of IP value
The country’s Constitutional Court, which split down the middle, refused to grant an appeal to challenge a Merck patent on new grounds
Patent focus has shifted to energy storage as cost-effectiveness achieved for wind and solar power, but the failure to address the role of IP hinders transfer mechanisms
IAM's annual benchmarking survey is designed to identify the key concerns of senior decision makers in areas such as deal-making, valuation, patent office performance, top litigation venues and policy
New IAM research reports identify the key trends shaping the global IP market – and tell you how to respond
The key takeaways from WIPO’s 2018 IP indicators report
New report claims status of US, EU and UK as leading innovators under threat as they struggle to maximise return on R&D investment.
In June’s round-up of life sciences-related news, we report on the US Supreme Court’s decision to grant certiorari in the Helsinn Healthcare v Teva Pharmaceuticals Section 102 dispute, but not in the Cleveland Clinic’s Section 101 case against True…
New IP policy looks to get tough on evergreening in pharma industry but also brings country closer to international best practices.
Series of unique factors contributed to country's status as start-up hub but there are growing signs that more needs to be done to preserve it.
The US Department of Commerce has reportedly slapped tough restrictions on telecoms giant ZTE, in a move that could end many of its supplier relationships with US tech companies. Effective today, any company that wants to ship US-made hardware to…
While the global quarrel over the pricing of patented drugs continues unabated, Swiss pharmaceutical giant Novartis has announced that it will offer a number of its medicines at significant discount to developing countries.
According to a press…
IPBC Global in San Francisco is now finished, but only after another compelling day of sessions, networking and discussion. Here, IAM’s editorial team – Joff Wild, Richard Lloyd, Jack Ellis and Sara Jayne Clover – pick out a few of the highlights: